Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections³ and costimulation of T cell responses⁴. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).

1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
5. Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
6. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
7. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
9. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)

1. Dhariwala MO, et al. 2020. Cell Rep Med. 1:100132. PubMed
2. Fu J et al. 2019. Cell stem cell. 24(2):227-239 . PubMed
3. Dubrovsky L, et al. 2020. MBio. 11:. PubMed
4. Alroqi F, et al. 2017. J Clin Immunol. . 10.1007/s10875-017-0451-1. PubMed
5. Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
6. Gao H, et al. 2021. J Virol. :. PubMed
7. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
8. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
9. Jouand N, et al. 2018. PLoS Pathog. 14:e1007041. PubMed
10. Thakral D, et al. 2008. J Immunol. 180:7431. PubMed
11. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
12. Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed
13. Martins MA, et al. 2017. AIDS Res Hum Retroviruses. 33:843. PubMed
14. Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
15. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
16. Kong R, et al. 2019. Cell. 178:567. PubMed
17. Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed
18. Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed
19. Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed
20. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
21. Wastyk HC, et al. 2021. Cell. 184(16):4137-4153.e14. PubMed
22. Speir M,et al. 2017. Sci Rep.. 10.1038/s41598-017-14690-5. PubMed
23. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
24. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
25. Yang Q, et al. 2020. J Immunol. 2331:204. PubMed
26. Zheng Y, et al. 2022. iScience. 25:103785. PubMed
27. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
28. Schwabenland M, et al. 2021. Immunity. . PubMed
29. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
30. Nicolet BP, et al. 2017. J Immunol. 198:962. PubMed
31. Silva–Cardoso SC, et al. 2017. J Immunol. 199:253. PubMed
32. Majri SS, et al. 2018. J Immunol. 200:110. PubMed
33. Simon S, et al. 2018. Front Immunol. 1.7375. PubMed
34. Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed
35. Eriksson E, et al. 2017. Clin Cancer Res. 5.018055556. PubMed
36. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
37. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
38. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
39. Martin E, et al. 2020. JCI Insight. :5. PubMed
40. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed

Majority of thymocytes, T cell subset, NK cells

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.